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Abstract
Breast cancer is the second most common type of cancer among women, with an estimated 2.8
million diagnosed in the United States. Many cancers cannot be detected by their intrinsic
vascular contrast, especially in their early stages. This necessitates the use of an exogenous
contrast agent. Photoacoustic Imaging (PAI) and Fluorescence imaging (FI) are promising noninvasive in vivo cancer diagnostic methods. To further improve the tumor to background
contrast, researchers are investigating various exogenous contrast agents for PAI and
fluorescence imaging that target tumor vasculature and hypoxia.
This dissertation is structured into two main sections. In the first part, the evaluation of several
novel porphyrin dyes has been presented as PAI contrast agents in direct comparison to the
commonly used indocyanine green (ICG). Imaging of a sub-mm target containing quinolineannulated porphyrin up to 2 cm depth in a tissue-like matrix exceeds the performance of imaging
the similar target containing ICG, which suggests the use of quinoline-annulated porphyrins as
potential contrast agents for cancer detection using PAI. The second part of the dissertation
reports an investigation of the unsubstituted imidazole derivative as well as the 4-nitroimidazole
ICG-conjugate for targeting tumor hypoxia. The performance of 4-nitroimidazole dye by
imaging tumor cells in vitro and animals in vivo were validated, and the results with the 2nitroimidazole dye were compared, using the imidazole derivative as the reference. The results
demonstrated the efficacy of 4-nitroimidazole-ICG as a hypoxia targeting fluorescence probe and
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suggest the use of 4-nitroimidazole dye-conjugate as a hypoxia probe with a significant cost
reduction in the synthesis.
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Chapter 1
Breast Cancer and Optical Imaging

1-1
1-1.1

Introduction
Overview

Breast cancer is the second most common type of cancer, with an estimated 2.8 million
diagnosed breast cancer patients in the United States. The mortality rate is estimated at 17% in
the 232,340 patients diagnosed in 2013 [1]. This mortality rate can be drastically reduced by
early detection, however many cancers cannot be detected by their intrinsic vascular contrast,
especially in their early stages [2, 3]. This necessitates the use of an exogenous contrast agent.
Different contrast agents such as nanoparticles, gold nanoparticles containing organic dyes such
as ICG (indocyanine green) and porphysomes have been used [4-6]. Near-infrared (NIR) optical
imaging distinguishes itself from other imaging modalities by its features such as non-ionizing
radiation, noninvasive technology for imaging and quantifying vascularity, multimodal imaging,
cost effectiveness and its ability for real time data acquisition. Near Infra-red imaging have better
tissue penetration, less autofluorescence, and large Stokes shifts. Near-infrared fluorescence
imaging and the use of nitroimidazoles as exogenous probes has received great attention because
of their unique behavior in hypoxic environments owing to their high electron affinity [15-17].
Nonetheless, Photoacoustic Imaging (PAI) and Fluorescence imaging are promising noninvasive in vivo diagnostic methods. PAI provides optical contrast at ultrasonic imaging
resolution. To further improve the optical contrast, researchers are investigating various
exogenous contrast agents for PAI and fluorescence imaging that target tumor vascularity with
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appropriate tumor-specific ligands and target tumor hypoxia [7-10]. PAI has an advantage over
other imaging modalities such as MRI and CT by its non-ionizing effect, the absence of
radioactivity, and its combined high ultrasonic resolution and high optical contrast.

This research focuses on the identification and evaluation of next generation novel
contrast agents that may significantly enhance the effectiveness of PAI in early visualization of
breast cancer. The overarching goal of this research is to increase the optical contrast in PAI and
improve tumor hypoxia targeting using fluorescence imaging modality, to enable early detection
of cancerous tumors resulting in decrease or morbidity and mortality in patients.

1-1.2

Photoacoustic principle

Photoacoustic phenomena was first described by Alexander Graham Bell in 1880 [12]. The lack
of strong light sources caused further research on the application to cease soon after. With the
development of lasers in the early 1970s, photoacoustic spectroscopy was revived. Lasers
provided high intensity light at a tunable frequency, which allowed an increase in sound
amplitude and sensitivity. The basic principle of the photoacoustic phenomena can be described
as a chromophore or a particle absorbs a pulsed radiation energy, the absorbed energy is
converted into heat and the temperature of the object increases. This rise in temperature causes a
thermal expansion, generating an acoustic wave in the medium [11]. By detecting these acoustic
waves using an ultrasound transducer and processing them using a beamforming algorithm,
photoacoustic images are formed. PAI can reconstruct light absorption map inside the biological
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tissue. The photoacoustic wave generation is described by the general photoacoustic equation
[23]

(1)

where p(r, t) denotes the acoustic pressure at location r and time t, vs denotes the speed of sound
(∼1480 m/s in water), β denotes the thermal coefficient of volume expansion (∼4×10−4 K−1 for
muscle), H is the heating function defined as the thermal energy converted per unit volume and
per unit time; it is related to the optical absorption coefficient μa and fluence rate Φ by H = μaΦ
and Cp [∼4000 J/(kg·K) for muscle] denote the specific heat capacity at constant pressure. The
left-hand side of equation (1) describes the wave propagation, whereas the right-hand side
represents the source term. For a short laser pulse that satisfies the assumption that the laser
pulse duration is less than the acoustic confinement time, which is less than the thermal
confinement time, the following thermal equation holds:

,

(2)

where T denotes the temperature rise and Cv denote the specific heat capacity at constant
volume.

Using the forward solution, the general photoacoustic equation can be solved by the
Green’s function approach which is defined as the response to a spatial and temporal impulse
source term, assuming an infinite space, where no boundary exists
3

, (3)

which represents an impulse diverging spherical wave, where r’ and t’ denote the source location
and time, respectively. Applying the Green’s function approach, we get

, (4)
which represents the pressure in response to an arbitrary source. Here, κ denotes the isothermal
compressibility. By substituting, simplifying and approximating the heat function Ht(t’)=δ(t’) we
get

, (5)
which can be used to compute photoacoustic pressure generated by an arbitrarily heterogeneous
optically absorbing object.

1-1.3

Fluorescence Imaging

In fluorescence imaging, photons are absorbed by a fluorescent molecule, and emits light
(fluoresces) at a longer wavelength in order to return from its excited state to its ground energy
state in a certain period of time. This emitted light can be captured with CCD (charge-couple
device) camera or detectors, and the quality of the detection will rely mainly on the capacity to
filtrate the emitted photons from the illumination light. The absorption of light is connected with

4

an electronic transition from the ground state to an excited stated of the molecule. The light
passing through a layer of thickness d is attenuated and described as

I(λ) = Io exp(-µad) = Io 10-ελ Cab d , (6)
where I(λ) is the transmitted light intensity, Io is the incident intensity, ελ is the molar extinction
coefficient and Cab is the concentration of the absorbing molecule [13]. In scattering samples, the
absorbing coefficient µa and the scattering coefficient µs sums up. The molecule fluorescence
intensity or quantum flux corresponds to the intensity equation

IF(λ) = Io [1 – 10-ελ Cab d ] ΦF

Ω
π

,

(7)

where ΦF is the fluorescence quantum yield and Ω the angle of detection of the isotropic
fluorescence radiation. In case of thin samples such as cells or biopsies with thickness in the
micrometer range the fluorescence intensity equation can be approximated as
Ω

IF(λ) = Io ln10-ελ Cab d ΦF , (8)
π

which implies that fluorescence intensity is proportional to the concentration and the
fluorescence quantum yield of the absorbing molecule.
The fluorescence quantum yield (ΦF) is the ratio of photons absorbed to photons emitted
through fluorescence. In other words the quantum yield gives the probability of the excited state
being deactivated by fluorescence rather than by another, non-radiative mechanism. The most
reliable method for recording the quantum yield is the comparative method [14], which involves
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the use of well characterized standard samples with known fluorescence quantum yield values.
Essentially, solutions of the standard and test samples with identical absorbance at the same
excitation wavelength can be assumed to be absorbing the same number of photons. Hence, a
simple ratio of the integrated fluorescence intensities of the two solutions (recorded under
identical conditions) will yield the ratio of the quantum yield values based on the following
equation

, (9)
where the subscripts ST and X denote standard and test respectively, Φ is the fluorescence
quantum yield, Grad the gradient of integrated fluorescence intensity versus absorbance, and η
the refractive index of the solvent used.

1-1.4

Tumor angiogenesis

Tumor angiogenesis is the proliferation of a network of blood vessels that penetrates into
cancerous growths, supplying nutrients and oxygen, and removing waste products. This process
starts with cancerous tumor cells releasing signaling molecules to surrounding normal host tissue
which in turn activates certain genes in the host tissue which make proteins to encourage growth
of new blood vessels. Furthermore, the increased demand of oxygen due to the hyper metabolism
of tumors reduces the oxygen saturation of the hemoglobin content within the surrounding tissue
as seen in Figure 1-1. Multi-wavelength optical imaging reveals both angiogenesis and hyper
metabolism, both of which are important hallmarks of tumor proliferation, growth, and

6

metastasis [18-19]. Angiogenesis is considered one of the fastest growing fields in biomedical
research, and advances in our basic understanding of this process and its application have been
rapid.

Tumor hypoxia leads to an increased level of regulatory transcription factors such as
hypoxia inducible factor (HIF-1α) to upregulate the expression of genes associated with tumor
initiation, malignant progression, metastasis and resistance to chemotherapy and radiotherapy
[20-22,26]. However, the effects of angiogenesis remain controversial. HIF-1α protein
expression is similar in normoxic and hypoxic conditions but tends to stabilize in hypoxic
environments. HIF-1α combines with HIF-1β and activates several HIF-1 target gene to express
proteins, such as VEGF (Vascular endothelial growth factor), which is a significant protein
involved in angiogenesis.[24,27] Hence, many studies indicate that most solid tumors, regardless
of site of origin, contain hypoxic regions of biological and clinical significance. [25]
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Figure 1-1 The vasculature structural differences of normal and malignant tissues. Normal tissues have
relatively uniform and well-ordered blood vessels that are sufficiently close together to oxygenate all of
the tissue, blood vessels in tumors are tortuous, have incomplete vessel walls, have sluggish and irregular
blood flow, and have regions of hypoxia between the vessels. (Image from Ref. 20)

1-1.5

Statement of work

The overarching goal of this research is to increase the optical contrast in PAI and improve
tumor hypoxia targeting using fluorescence imaging modality, to enable early detection of
cancerous tumors resulting in decrease or morbidity and mortality in patients. This dissertation is
structured into two main sections. Chapter 2 introduces the evaluation of several novel porphyrin
dyes as PAI contrast agents in direct comparison to the commonly used indocyanine green (ICG)
and blood. Imaging of a sub-mm target containing quinoline-annulated porphyrin up to 2 cm
depth in a tissue-like matrix exceeds the performance of imaging the similar target containing
ICG, which suggests the use of quinoline-annulated porphyrins as potential contrast agents for
cancer detection using PAI. Chapter 3 of the dissertation reports an investigation of the
unsubstituted imidazole derivative as well as the 4-nitroimidazole ICG-conjugate for targeting
tumor hypoxia using fluorescence imaging modality. The performance of 4-nitroimidazole dye
has been validated by imaging tumor cells in vitro and animals in vivo and compared the results
with the 2-nitroimidazole dye, using the imidazole derivative as the reference. Histology images
of tumor stained sections was performed to confirm hypoxic condition of mice groups.
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Chapter 2
Porphyrin-derived photoacoustic contrast agents

2-1

Introduction

Photoacoustic imaging (PAI) is a non-invasive biomedical imaging modality that combines
optical and ultrasound imaging in such a way that its key characteristics are superior to each of
the component imaging techniques.[1-4] The absorption of a light pulse by a chromophore
causes a rapid and transient rise in temperature (in the order of mK), leading to a localized
thermal-elastic expansion. As a laser beam pulsed in the nanosecond range is scanned through an
object to be imaged, the emitted ultrasonic wave profile is acquired with standard ultrasonic
transducers. The data are used to reconstruct 2D or 3D optical absorption maps. PAI combines
the advantages of high optical contrast and ultrasound (sub-mm) spatial resolution.[1, 5-7]

Using the high optical absorption of the endogenous chromophore hemoglobin, PAI
proved itself as a powerful tool for imaging the blood content of, for instance, the vascular
network of cancers in rodent brains or ovary tissues, in mesoscopic biological objects, or present
in whole animals.[8-12] However, to achieve a good signal to noise ratio in reasonably short
time that would make PAI of deeply-seated lesions practical, the sensitivity of PAI at greater
tissue depths needs to be improved.[5] Furthermore, many cancers, particularly in their early
stages, cannot be detected by their intrinsic vascular contrast.[13] These current shortcomings in
PAI suggest the use of exogenous contrast agents.

The native light absorption of tissue is wavelength-dependent, with the least absorbance
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in the NIR region. For instance, the wavelength of maximum penetration of breast tissue is ~725
nm; whole blood has an absorption minimum at ~710 nm.[14] Thus, using near-infrared
wavelengths within the ‘spectroscopic window’ (~700-1000 nm) allows tissues to be imaged at
deeper depth (several cm) than most other optical imaging techniques. It thus follows that a good
PAI contrast agent ought to have a strong absorption in NIR, particular in the region between
~700 and 800 nm. Currently, the maximum photoacoustic imaging depth of 8.4 cm have been
achieved in chicken breast tissue.[47] Internal light delivery has also been proposed to image
organs beneath the skin.[48] Recently, a dual-modality photoacoustic and ultrasonic imaging
system to noninvasively detect sentinel lymph nodes based on the accumulation of methylene
blue dye has been developed.[49] Zackrisson, et al. reviewed the recent advances of
photoacoustic imaging in biomedical research, and discussed of strategies for clinical translation
of the PAI technique. Including its use as a noninvasive imaging of the breast, sentinel lymph
nodes, skin, thyroid, eye, prostate, and ovaries (transvaginal); minimally invasive endoscopic
imaging of gastrointestinal tract, bladder, and circulating tumor cells (in vivo flow cytometry);
and intraoperative imaging for assessment of tumor margins and metastases.[50]

The FDA-approved ocular angiographic dye indocyanine green (ICG) and ICG
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derivatives fulfill this spectroscopic requirement.[15] ICG is confined to the vasculature space
and it clears rapidly (t1/2 < 3 min), complicating longitudinal in vivo studies. This lead to the
development of other contrast agents, such as metal-based nanoparticles combined with and
without organic dyes, nanotubes, and porphyrin-based liposomes.[16-34] Water-soluble
polydopamine and linear melanin have also been tested as contrast agent for photoacoustic
imaging with an imaging depth of 12 mm.[51] Since the safety of the use of nanoparticles in
medicine is unclear so far,[35] it led to the search for novel ways to, for instance, generate dyes
in tissue.[7, 36, 37] For instance, photoacoustic probes activatable by cancer markers were
developed.[38, 52] Notably rare from all these reports are novel small molecular dyes as PAI
contrast agents.[39, 40]

2-2

Methods and Procedures
2-2.1 Materials

The group of Prof. Christian Brueckner in the Department of Chemistry at the University
of Connecticut has synthesized six free base tetrapyrrolicchromophores, three of which are
quinoline-annulated porphyrins dyes 1 through 3 prepared from TPP as described in the
literature,[41] and three morpholinobacteriochlorins dyes 4 through 6 (listed in Figure 2-1) were
also prepared from TPP as described.[42] These agents exhibit a broad optical absorption
profiles in the near-infrared window (~700-850 nm) and possess, in comparison to regular
porphyrins, unusually low fluorescence emission and 1O2 quantum yields. ICG was purchased
from Sigma Aldrich. The dyes 1 through 3 and ICG were also tested in an aqueous solution using
the FDA-approved excipient Cremophore EL®, at A = 1.0 at the wavelengths listed in Table 2-2
at 1 cm and 2 cm path lengths).. The dyes 1 through 6 and ICG were also dissolved in DMF at a
13

concentration so that they possessed all identical absorbances (A = 1.0 at the wavelengths listed
in Table 2-3 at 1 cm and 2 cm path lengths).
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Figure 2-1 Structures of the NIR chromophores investigated.

The UV-Vis absorption spectra for all compounds 1 through 6 shown in Figure 2-2 were
recorded using a Cary 50 spectrophotometer (Varian Analytical Instruments, Walnut Creek, CA).
The reported results indicate a strong optical absorbance wavelengths between 700 and 900 nm.
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Figure 2-2 UV-Vis spectra of the chromophores in DMF used in the PAI experiments. The
concentrations were adjusted to an absorption value of 1.0 0.05 at the respective max wavelength, 1 cm
glass cuvette.

The photophysical properties are associated with the molecule energy behavior upon
absorption of light. The molecular absorbance and emission of light was first described by
Aleksander Jablonski. In his diagram he explains how electrons are excited from the ground state
into higher electronic energy states called singlet states, and the events that occur as these excited
molecules relax by photon emission and other mechanisms to eventually fall back into the
ground-level energy state. As you can see in Figure 2-3, excited states are short-term, so the
relaxation back to the ground state happens through emitting fluorescence or thermally emitting
light quanta through internal conversion (IC). Another possibility that an electron undergo an
intersystem crossing ISC process transitioning from a singlet state to a triplet state, the relaxation
from an excited triplet state to the ground singlet state, is either through phosphorescence or,
through interaction with triplet oxygen (3g), generating singlet oxygen (1g).
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Figure 2-3 Jablonski diagram: When a molecule absorbs light, it undergo a transition into an excited
singlet state, from there the system either relaxes back to the ground state through fluorescence or
thermally through internal conversion (IC). It can also undergo an inter-system crossing (ISC) into an
excited triplet state where it relaxes either thermally, through phosphorescence or through interaction with
triplet oxygen, generating a singlet oxygen.

Thus, the photophysical parameters such as singlet state lifetime (τS1), the fluorescence
quantum yield (ΦFluo), the ISC quantum yield (ΦISC), and the singlet oxygen quantum yield (ΦΔ)
are crucial parameters to assess the relaxation pathways of the chromophores investigated. Some
of the photophysical properties in Table 2-1 were recorded in collaboration with A. Vollertsen,
as part of his MS Thesis, Humboldt-University, Berlin, 2012.
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Table 2-1 Photophysical properties of the dyes investigated
max/nm
ICG 776,d 794j
TPPa
648
k
1
728
k
2
726
3m
773
k,j
7
667
k,j
4
704
k,j,l
5
745
6k,j
790

log atmax/ Fluo/%
cm-1M-1
5.06
3.61
4.30
4.49
4.44
3.75
4.71
4.54
4.36

8g
9 (11)c
<1
<1
0.004
<1
17
3
0.01

ISC/%
(± 3%)

n
(± 10%)

S1/ns
(± 10%)

0.6h
50
2
b.d.e
–b
27
45
85
87

–i
45
5
<1
4o
7
40
–b
12

0.15h
0.24
0.04
b.d.e
0.74, 1.70f
1.33
5.40
3.77
0.45

a

In toluene.bNot determined. c G. H. Barnett, M. F. Hudson, and K. M. Smith, J. Chem. Soc. Perkin
Trans. I, 1975, 1401-1403.dAt 6.5 µM ICG in H2O, M. L. J. Landsman, G. Kwant, G. A. Mook, W. G.
Zijlstra, J. Appl. Physiol., 1976, 40, 575–583. eBelow the detection limit. f Biexponential decay. g J.
Pauli, R. Brehm, M. Spieles, W. A. Kaiser, I. Hilger, and U. Resch-GengerJ. Fluoresc., 2010, 20, 681–
693. hIn O2-free H2O. T. Luo, MSc Thesis, University of Waterloo, 2008. iWhile ICG does not appear to
generate much, if any, 1O2 upon radiation, it generates medicinally relevant reactive oxygen species: S.
Fickweiler, R.-M. Szeimies, W. Bäumler, P Steinbach, S. Karrer, A. E. Goetz, C. Abels, and F.
Hofstädter, J. Photochem. Photobiol. B, 1997, 38, 178–183.jRef. 22. kmax and log  in CH2Cl2, all else in
DMF. l Data for the closely related meso-tetraphenyl derivative. mmax and log  in CH2Cl2, all else in
DMSO. nexcitation = Soret. o At excitation = 625 nm, = 21%, a finding rationalized by the presence of
non-sensitizing dimers that are excited at Soret

2-2.2 Photoacoustic System Description

The PAI system has been designed in our laboratory, which allows connection of any type of
ultrasound transducer array with a maximum of 64 elements and center frequency scalable with
the central frequency and bandwidth of the ultrasound transducer between 1 and 10 MHz. The
two receiving units of 32-channels each amplify channel data independently by 20 dB before
32:1 multiplexing. Then, the outputs of the two multiplexers are further amplified by two
independent two-stage variable gain amplifiers and filtered with 0.5-10 MHz band pass filters.
The total gain of the system is typically set to 60 dB. The achieved imaging speed of this system
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in PA mode is 5 frames per second. The system utilizes a unique field programmable gate array
(FPGA) based reconfigurable processor that allows real-time switching and interlacing between
the two imaging modalities (i.e. ultrasound and photoacoustic imaging).The system features a
modular design and the ability of real-time parallel acquisition from 64 channels with each
channel sampled at 40MHz.[43]

Photoacoustic images were reconstructed using a typical delay and sum algorithm based
on the transducer array geometry. These images were then plotted using a color scale. A tunable
Ti-Sapphire laser (Symphotics TII, LS-2134; Symphotics, Camarillo, CA), optically pumped
with a Q-switched Nd:YAG laser (Symphotics-TII, LS-2122), operating in the spectral range of
700nm-1000 nm, was used to illuminate the tubing target with an average power of radiant
exposure of 18 mJxcm-2, i.e., well below the ANSI limits of 21 mJxcm-2, for the shortest
wavelengths used.[44] The optical wavelengths used for each dye based on the peak value of the
UV-Vis absorption data are given in Table 2-3.

2-2.3 Photoacoustic Phantom Studies

The feasibility of the porphyrins to serve as PAT contrast agents was tested first using a coregistering ultrasound and photoacoustic imaging system. Tubing was imaged while injecting
different porphyrin-based and benchmark (ICG) contrast agents. An Nd:YAG laser set at 745
nm, 19.0 mW power to illuminate the samples was used. Photoacoustic measurements were
taken for each sample with a single element ultrasound transducer connected to a Panametrics
5073PR for amplification and filtering. The dyes have shown enhanced photoacoustic
measurement over the ICG benchmark used. The monoquinoline-fused dye 3 diluted at 500
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micro Molar was first used which resulted in 3.7 v signal power, and the bis-quinoline-fused Noxide dye 1 diluted at 400 micro Molar resulted in 3.8 v signal power while ICG resulted in 2.02
v signal power under the same measurement conditions. These results encouraged us to further
evaluate the PAI signal strengths and compare them to blood and ICG.

The phantom studies to evaluate the dyes relative to ICG were performed using the set-up
shown in Figure 2-4. A translucent polyethylene tube with an inner diameter of 0.38 mm and
outer diameter of 1.09 mm was filled with the standard solutions of the dyes 1 through 6, ICG
and day-old whole rat blood using a manual syringe. The tube was immersed at 1 and 2 cm
depths in a tank filled with a 4% intralipid suspension (absorption coefficient µa = 0.01 cm-1,
reduced scattering coefficient µs’= 4 cm-1.[45] Both ends of the tubing comes out of the tank.
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Figure 2-4 PAI experimental setup. Details: Nd:YAG-pumped tunable Ti:Sapphire laser, average power
of 18 mJcm-2; ultrasound transducer of central frequency 1.3 MHz and bandwidth of 80%, connected to
a 64 channel ultrasound PAI system.

Porphyrin solutions were injected one by one into the tubing and tested, after every
measurement the tube will be flushed with alcohol twice followed by each injection. The
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samples are then recollected from the other end of the tube. A different syringe was used for each
dye to avoid contamination. Upon illumination with an NIR laser tuned to the max of the dye
investigated (Table 2-3) and spread to 2 cm diameter width at the point where it intersected with
the tube. The photoacoustic measurements were recorded for each sample solution using a
commercial low-frequency transducer array (produced by Vermon, France), and consisted of 64
elements with 0.85 mm pitch. The center frequency of the transducer was 1.3 MHz and
bandwidth of 80%, connected to a 64 channel ultrasound PAI system. The array was held at 1
and 2 cm, respectively, away from the center of the intersection of the NIR beam and the tube.
The signal was then collected and processed by the PAI system. Photoacoustic images were
reconstructed using a typical ultrasound beam forming algorithm based on the transducer array
geometry.

2-3

Results and Discussion

Chromophores 1 through 6 were selected for this investigation because of their UV-Vis NIR
absorption properties. Their max values (the wavelengths of the band of longest absorption) in
DMF between 726 nm and 790 nm fall into the spectroscopic window of tissue, and all fall
within a range of 70 nm of those of ICG in the same solvent as seen in the graph in Figure 2-2,
allowing for a meaningful direct comparison of the PAI data accrued. Upon light absorption,
porphyrins generally undergo a ππ* transition into an excited singlet state. From there the
system either relaxes back to the ground state through fluorescence or thermally through internal
conversion (IC). It can also undergo an inter-system crossing (ISC) into an excited triplet state.
In turn, the triplet state relaxes either thermally, through phosphorescence or, frequently
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observed in porphyrins, through interaction with triplet oxygen (3g), generating singlet oxygen
(1g). Thus, the singlet state lifetime (τS1), the fluorescence quantum yield (ΦFluo), the ISC
quantum yield (ΦISC), and the singlet oxygen quantum yield (ΦΔ) are crucial parameters to assess
the relaxation pathways of the chromophores investigated.

Two series of experiments were performed. In one, solutions of the dyes 1 through 3
and ICG in PBS/1% DMF/1% Cremophore EL® were prepared at concentrations that resulted
all solutions to possess an equal absorption at  max (O.D. of 1.0 at 1 cm path length, see
Figure 2-2), and was irradiated at max. Since all solutions absorbed within a narrow
window, the energy input difference between the extremes of max is less than 9%.
Empirically, the data of the PAI experiments was found to vary upon replication by up to
7%, i.e. the simplification of using different irradiation wavelengths/energies at equal
absorbance values is within acceptable limits. The phantom studies described below were
performed, the results of which are listed in Table 2-2.

Table 2-2 Comparison of the PAI signal strengths in the phantom study

irradiation/nm

Relative PAI signal
strength at 1 cm depth

Relative PAI signal
strength at 2 cm depth

ICG
1

790
765

1.0
1.6

1.0
1.5

2

755

1.4

1.4

3

780

1.0

1.1

To allow a much better direct comparison of the PAI signal strength generated by
ICG, a blood sample and any given dye, and to allow a correlation to the photophysical data
22

measured primarily in DMF (Table 2-1), a second series of experiments was set up. The
spectra of the dyes 1 through 6 all overlap with the spectrum of ICG. Thus, DMF solutions of
the dyes and ICG were prepared and the isoabsorbance point for each dye-ICG pair was
determined. Then, the concentration of the solutions was adjusted to an O.D. of 1.0 at the
isoabsorbance wavelength (at 1 cm path length; see Table 2-3 for the irradiation used), thus
assuring that each ICG-dye pair would receive the identical energy input upon irradiation at
this wavelength. The blood sample was used as is and irradiated at 750 nm, an arbitrary
wavelength in the middle of the range of the irradiation used.

The phantom studies to evaluate the dyes relative to ICG were performed using the
set-up shown in Figure 2-4. A translucent polyethylene tube with an inner diameter of
0.38 mm was filled with the standard DMF solutions of the dyes 1 through 6 and ICG. The
tube was immersed at 1 and 2 cm depths in a tank filled with a 4% intralipid suspension, a
white opaque emulsion of soy bean oil, egg phospholipids and glycerin. This emulsion is
widely used to simulate the scattering properties of biological tissues at wavelengths in the
red and infrared ranges, where tissue is highly scattering but has a rather low absorption
coefficient.[45]
Upon illumination with a NIR laser tuned to the irradiation chosen and spread to 2 cm
diameter width at the point it intersected with the tube, the photoacoustic measurements were
recorded for each sample solution using a commercial low-frequency transducer array. The array
was held at a fixed position 1 cm and 2 cm away from the center of the intersection of the NIR
beam and the tube, respectively. The PA signal was collected and processed by a PAI system.
Photoacoustic images were reconstructed using a typical ultrasound beam-forming algorithm
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based on the transducer array geometry. The data thus obtained were plotted using a color scale,
providing the photoacoustic images shown in Figure 2-5. The PAI signal strengths relative to
those obtained for ICG in the same solvents are listed in Table 2-3.

Table 2-3 Comparison of the PAI signal strengths in the phantom study for dyes 1-6 in solvent DMF

ICG
blood
1
2
3
4
5
6

irradiation/nm

Relative PAI signal
strength at 1 cm depth

Relative PAI signal
strength at 2 cm depth

790
750
765
755
780
715
765
741

1.0
1.1
2.5
1.9
1.7
Below detection
0.5
0.8

1.0
1.0
2.4
1.2
1.1
Below detection
0.5
0.7

At 1 cm depth/detector distance, all dyes tested provide a clear image of the target.
However, the intensity of the signal varied. The signal strengths recorded for the quinolineannulated porphyrin 1 through 3 are 1.7 to 2.5-fold stronger than the signal for the benchmark
compound ICG or the blood sample (that showed very similar PAI signal strengths to those
obtained with ICG) with compound 1 providing the best signal. The signal strength recorded for
dye 1 is still nearly 2.4-fold stronger at 2 cm immersion depth/detector distance, though the
relative advantages of these dyes in DMF over ICG are largely eroded. A comparison of the
photophysical data for the dyes (Table 2-1) with the PAI data in (Table 2-3) reveals that the best
PAI contrast agent 1 is mostly differentiated from the other two structurally similar compounds
(and ICG) by possessing the shortest singlet state lifetime, suggesting that this may have been the
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crucial factor for its relatively high efficacy.[46] Using an aqueous solvent for the comparison of
the three dyes with ICG, the absolute signal strength and the relative signal strength advantages
of the dyes 1 through 3 are not as strong. Given the lower heat capacity of DMF (1.88 JK-1cm-3)
compared to that of water (4.19 JK-1cm-3) (and ignoring factors such as their varying thermal
pressure coefficients),[46] the lower light absorption-induced photoacoustic pressure in water
does not surprise. The fact, however, that the relative drop of the signal strengths with phanton
immersion depth/detector distance is not as steep when using the aqueous solvent versus DMF,
does not find a simple explanation.

As a result of the higher signal-to-noise ratios, the PAI images recorded with dyes 1 and
2 also show a better-defined tubing structure than the image recorded with ICG (Figure 2-5);
note that the images shown were recorded using aqueous solvents. The signal strength
recorded for 3 (no image shown) was identical to that recorded for ICG. However, the ~4fold higher absorptivity of ICG compared to the porphyrinoids at around 750 nm suggest that
ICG is still a better contrast agent at equal concentrations. As it could be predicted based on
their higher fluorescence quantum yields, larger ISC yields, longer-lived excited singlet
states, and higher singlet oxygen quantum yields, the bacteriochlorins 4 through 6 did not
perform as well as the quinoline-annulated porphyrins or ICG in the PAI experiments. This
illustrates well the need to fine-tune all photophysical properties of a potential PAI imaging
dye, not just their optimal absorption properties.
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Figure 2-5 Photoacoustic images of the dyes indicated, dissolved in an aqueous solution containing the
surfactant Cremophore EL to a concentration resulting in an absorbance value of A = 1.0 at 1 cm path
lengths. Left column: Targets located at 1 cm depths, right column targets locates at 2 cm depths. Targets:
a transparent polyethylene tube of inner diameter 0.38 mm and outer diameter 1.09 mm filled with the
dye solution, submersed in an opaque 4% Intralipid suspension. To best visualize the contrast, the
dynamic range of the display was set to 10 dB.
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2-4

Summary

Direct comparison was performed for a range of porphyrinoids with NIR absorbing properties
belonging

to

two

different

compound

classes

(quinoline-annulated

porphyrins

and

bacteriochlorins) as exogenous PAI imaging contrast agents in phantom studies. Also
demonstrated the imaging of a sub-mm target at up to 2 cm depth in a tissue-like matrix whereby
some porphyrinoids matched or exceeded the performance of the benchmark dye ICG at equal
absorbance or the performance of pure blood. This suggests the use of quinoline-annulated
porphyrins as potential contrast agents for in vivo use for multi-cm deep tissue PAI. While this
data does not allow any obvious direct correlations between the photophysical data and the PAI
contrast enhancement measured to be made, the need for the ability of the dyes to access a very
efficient thermal relaxation pathway is once again highlighted. Moreover, more members of
NIR-absorbing porphyrinoids are being screened using a simple and rapid screening tool such as
the one used here, a direct correlation between the PAI signal strength and key photophysical
parameters may come into focus, further assisting in the design of optimized contrast agents. The
best contrast agents identified in this study, the two quinoline-annulated porphyrins, are currently
undergoing a range of in cyto and in vivo cytotoxicity and PAI studies.
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Chapter 3
Dicarboxylic Acid ICG Derivatives Fluorescence Contrast agents

3-1

Introduction

Tumor hypoxia, defined as an oxygen-deprived condition, has been characterized as
having detrimental effects on treatment resistance. Hypoxia is a characteristic feature in most
solid tumors due to the imbalance between new blood vessel formation and rapid proliferation of
cancer cells. [1-3] The interest in tumor hypoxia has been recognized for more than 60 years.[4]
Several factors contribute to inadequate oxygen transport and hypoxia, including low vessel
density and increased oxygen consumption. Angiogenesis promoted by the tissue itself emerges
as a strategy to meet oxygen demand. However, tumor growth often exceeds the capacity of
accompanying blood vasculature to deliver adequate quantities of oxygen to the growing cell
mass.[5-6,41] The development of effective hypoxia probes can help visualize the tumor
development and would impact the current strategies for early tumor detection and diagnosis in
improving the outcome of cancer treatment. Additionally, the ability to non-invasively image the
early events of tumors will enable the tracking of tumor progression and metastases.[7-16,42]
That is of significant value, specially that this phenomenon begins to emerge when the diameter
of solid tumor reaches 0.35 mm.[2,40] However, in vivo imaging of the early development of
tumor remains a great challenge due to the limitations in the sensitivity of current molecular
imaging probes, delivery of the probes and the interference of intrinsic background signals.[1719]

32

A recent review on the biology of hypoxia,[39] indicates that quantification of tumor
hypoxia can be performed directly or indirectly, and with exogenous or endogenous markers.
Tumor cells can launch various intracellular signaling pathways to survive hypoxia, such as HIF1–mediated gene expression, the unfolded protein response, and AKT-mammalian target of
rapamycin signaling. These pathways prompt aggressive, metastatic, and treatment-insensitive
tumors and are considered potential targets for therapy. Hypoxia leads to important, but
unfortunately not well-understood changes in microRNA expression, epigenetics (study of
variations that are caused by external factors that switch genes on and off and affect how genes
being read by cells), and metabolism.

Near-infrared fluorescence imaging has emerged as a sensitive tool for non-invasive
cancer imaging,[20-28] and the use of nitroimidazoles as exogenous markers has received great
attention because of their unique behavior in hypoxic environments owing to their high electron
affinity. This is a well-studied class of molecular probes that target tumor hypoxia by
nucleophilic covalent binding to proteins in environments of low pO2 (<1.5% O2).[29-33] A 2nitroimidazole-indocyanine green (ICG) conjugate was recently reported to persist in the tumors
for a significantly longer period than ICG as shown by NIR-fluorescence tomography,[29, 31,
32, 34-37] suggesting a possible application of the hypoxia selectivity of 2-nitroimidazole family
for in vivo fluorescence imaging.

3-1.1 Nitroimidazole-piperazine-ICG

In an earlier study, the biodistribution of a new generation of hypoxia probe, 2nitroimidazole ICG conjugate, with two carbon atoms less in the polyene linker was studied in
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murine tumor model in vivo. The results were compared with an earlier version of the hypoxia
probe that was synthesized with an ethanolamine linker. The in vivo experiments were conducted
with balb/c mice and the new 2-nitroimidazole ICG conjugate showed more than twice the
average in vivo fluorescence intensity in the tumor beyond two hours post injection as compared
with the older version of the piperzine-2-nitroimidazole-ICG. These initial results suggested that
the modified 2-nitroimidazole ICG may significantly improve in vivo tumor hypoxia targeting.
[43] However, synthesizing 2-nitroimidazole ICG is a very complicated, time-consuming process
and expensive. In order to overcome these obstacles, 4-nitroimidazole-ICG using piperazine
linker to conjugate the 4-nitroimidazole and bis-carboxylic acid ICG (4-nitroimidazolepiperazine-ICG) moieties was synthesized for tumor hypoxia targeting using fluorescence
imaging. The 4-nitro hypoxia conjugate is easier and considerably cheaper to make compared to
the 2-nitro probe. The hypoxia targeting performance of the 4-nitroimidazole-piperazine-ICG
hypoxia probe was compared with the previously tested 2-nitroimidazole-piperazine-ICG and
imidazole-ICG in tumor bearing mouse model in vivo and data acquired validated the
performance in vitro in tumor cells. Results with 4-nitroimidazole-piperazine-ICG had shown
great potential and were had similar results compared to 2-nitroimidazole ICG.
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3-2

Synthesis of 4-nitroimidazole-ICG Dye Conjugates

In collaboration with the group of Prof. Michael Smith in the Department of Chemistry at the
University of Connecticut, 4-nitroimidazole-ICG conjugate has been synthesized using
piperazine linker to conjugate the 4-nitroimidazole and bis-carboxylic acid ICG (4nitroimidazole-piperazine-ICG) moieties. Briefly, the 4-Nitroimidazole (1 g, 8.85 mmol) was
added to a mixture of methyl bromoacetate (0.84 mL, 8.85 mmol), potassium carbonate (1.8 g,
13.27 mmol), and TBAI (0.070 g, 0.185 mmol) in 10 ml of acetonitrile. The mixture was heated
to 80°C, and stirred vigorously at this temperature for 40 min. After cooling the ambient
temperature, the inorganic salts were removed by vacuum filtration and washed with acetonitrile.
The filtrate and washings were combined and the solvents evaporated in vacuo to give a residue
that was recrystallized from ethyl acetate. (1.46 g, 7.87 mmol, 89%).Mp, 129-130°C. 1H NMR
(DMSO): δ 8.37 (s, 1H), 7.82 (s, 1H), 5.10 (s, 1H);

13

C NMR (DMSO): δ 168.5, 147.3, 138.8,

123.0, 53.0, 48.7. [34]

UV-Vis absorption and fluorescence spectra for 4-nitroimidazole-ICG in Figure 3-1
show a maximum absorption peak of 755 nm. The fluorescence spectra were detected with an
excitation wavelength of 710 nm and had a maximum emission peak at 790 nm. The spectra
shown were recorded using Varian Cary 50 UV-Vis spectrophotometer. The extinction
coefficient for the 4-nitroimidazole-ICG conjugate is 207,519 M-1cm-1 and the calculated
quantum yield is 0.07 as per the procedure discussed in section 1-1.3.
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Figure 3-1 UV-Vis NIR absorption and fluorescence spectra for 4-nitroimidazole-ICG.

3-3

Methods and Procedures
3-3.1 In vitro Experiments

Hypoxia-dependent targeting of the dye was assessed in vitro using 4T1 breast cancer cells.
Twelve dishes (T7425-2 60 mm x 15 mm surface-modified polystyrene tissue culture dishes (BD
Falcon, Franklin Lakes, NJ, USA)), each having approximately 1 million tumor cells were
evaluated. One group of six dishes was exposed to hypoxic conditions (5% CO2, 1% O2, 94% N2,
37°C) by passing the gas mixture into a hypoxic chamber (Billups-Rothenberg, Inc., Del Mar,
CA, USA) (Figure 3-2) for 10 min, the gas pressure was maintained at 5 psi throughout the 10
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min passage and the chamber was then sealed and incubated for 15 h. The gas mixture was
provided by Airgas East (Cheshire, Connecticut).

Figure 3-2 Hypoxic chamber

The second group of six dishes was incubated under normoxic conditions (5% CO2, 95%
O2, 37°C) for the same period. Two dishes from each group were treated with 3 ml of 15 μM 4nitroimidazole-ICG, two other dishes from each group were treated with 3 ml of 15 μM 2nitroimidazole-ICG, and two other dishes from each group were treated with 3 ml of 15 μM
imidazole-ICG. After the injection, the hypoxic group was put back into the hypoxic chamber
under the same conditions mentioned previously and re-incubated both groups for 9 h. The
medium was then removed and cells were rinsed with PBS to wash out free compounds and
immediately both groups were taken for imaging using the Lumina II Imaging System. Cells
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were then trypsinized to suspend the cells, and 2.5 ml of medium was added to each dish and
then transferred to a spectroscopic grade cuvette. The fluorescence emission spectra was
measured for each group using Varian Cary 50 UV-Vis spectrophotometer.

3-3.2 Tumor and Mice Imaging

In vivo tumor imaging experiments were performed using 4T1 Luc mammary carcinoma cells
grown in 6-8 week old BALB/c female mice. The animal protocol was approved by the
Institutional Animal Care and Use Committee of the University of Connecticut. 4T1 cells were
cultured in 89% DMEM (Dulbecco's Modified Eagle Medium (1X)), 10% FBS (Fetal Bovine
Serum, (Gibco, USA)) and 1% Pen/Strep (penicillin/streptomycin) and incubated at 37°C with
5% CO2. The 4T1 breast cancer cells were passed three times at 70% to 80% confluence in a
T75 flask (BD Biosciences, Bedford, Massachusetts) prior to injection, and 1×10^5 cells were
administered by subcutaneous injection into the right flank of the mice. The experiments were
performed when the tumor sizes reached approximately 7-8 mm in diameter.

Looking at the cultured dishes under the microscope confirms the status of the cultured
cells visually. In Figure 3-3 are three examples of cultured cells in three different stages, (a)
Freshly passed cells (b) 70-80% confluence cultured cells and (c) Trypsinized cells (detached).
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Figure 3-3 Cell culture examples

A group of five mice were injected intravenously through retro-orbital venous sinus with
100 µl of 4-nitroimidazole-ICG at 25 µM concentration. All injections and imaging experiments
were done under anesthesia by inhalation of 1.5% isoflurane and 1 L/m O2. While lateral tail
vein injection could be used for intravascular delivery of agents to mice, this procedure is
technically challenging and often has a high rate of failure, hence, retro-orbital injection was
chosen as an easier alternative reliable method for intravascular delivery of agents. Using IVIS
Lumina II Imaging System (described later), the tumor of each mouse was imaged pre-injection,
and then imaged for up to 60 min post-injection and then again at 2, 3, 4, 5, 6, 7, 8, 9, 10, 24 and
48 h. The mice were given a rest from anesthesia every hour. All animals recovered with no
adversarial effects due to these injections. Fluorescence intensity was averaged and compared.
After 48 h, mice were euthanized by cervical vertebra dislocation, and six organs including liver,
spleen, kidneys, lungs, heart and the tumor tissue were excised from the mice. Organs were
washed twice in PBS before acquiring florescence images for biodistribution analysis.
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The tumors were imaged using an IVIS® Lumina II Imaging System (Caliper Life
Sciences, Hopkinton, MA), which can provide visible light photographs and fluorescent images.
The IVIS Lumina II is capable of imaging both fluorescent and bioluminescent reporters. The
system is equipped with up to 21 filter sets that can be used to image reporters that emit from
green to near-infrared. All imaging experiments were performed using a 745 nm excitation filter.
The Living Image software yields high-quality, reproducible, quantitative results incorporating
instrument calibration, background subtraction and image region of interest analysis algorithms
(such as averaging, maximum and minimum, and brightness/contrast adjustment). The unit is
equipped with gas anesthesia ports and 5 position manifold within imaging chamber allow
anesthesia to be maintained during imaging sessions.

3-3.3 Immunohistochemistry (IHC)

Immunohistochemical staining was performed using the HypoxyprobePlus Kit (FITC-Mab) from
HPI Inc, to visualize the hypoxia tumor areas using an IHC technique. As recommended by the
protocol provided by HPI, 45 min before the animal was euthanized, 1.5 mg of
HypoxyprobePlus Kit diluted in 100 μl of 0.9% saline solution was injected intravenously
through retro-orbital venous sinus. Immediately after the animal was euthanized, the tumor
specimens were collected and fast frozen directly in liquid nitrogen until cryosectioned into 10
μm sections. The prepared sections were stored in −80 °C before staining. After thawing, the
sections were fixed in cold acetone for 10 min. Sections were incubated overnight at 4 °C with
rabbit anti-pimonidazol anti sera PA2627 diluted 1:20 in PBS containing 0.1% bovine serum
albumin and 0.1% Tween 20. The sections were then incubated for 60 min with FITC-conjugated
goat anti-rabbit antibody. Between all steps of the staining procedure, the sections were rinsed
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three times with PBS for 5 min each. Digital images of the stained sections were obtained using
Zeiss Axio Imager M2 Microscope. The percentage of hypoxic areas was analyzed using the
ImageJ program (National Institutes of Health, Bethesda, MD, http://rsb.info.nih.gov/ij/).

3-4

Results and Discussion
3-4.1 In vitro Hypoxia

The uptake of the dyes by both hypoxic and normoxic tumor cells was examined in culture
dishes, and compared the results with the putative control imidazole ICG. All compounds were
imaged using the Lumina II Imaging System described in the Experimental section. Figure 3-4
shows one set of three dishes of the hypoxic group marked as (a) dish treated with 15 μM of
imidazole ICG, (b) dish treated with 15 μM of 2-nitroimidazole-ICG and (c) dish treated with 15
μM of 4-nitroimidazole-ICG. The average radiant efficiency of the two separate sets was
measured at 3.61 (±0.32)×107 and 3.27 (±0.30)×107 for 4-nitroimidazole-ICG and 2nitroimidazole-ICG, respectively, compared to 1.79 (±0.4)×107 for the control dish of imidazole
ICG. A graphical representation in Figure 3-5 shows that dishes treated with 2-nitroimidazoleICG and 4-nitroimidazole-ICG resulted in the detection of significantly higher levels of
fluorescence in the cells cultured under hypoxia than those in cells cultured under normoxia
conditions. The average radiant efficiency of 1.04 (±0.03) ×107 and 1.22 (±0.11) ×107 was
measured for the 2-nitroimidazole-ICG and 4-nitroimidazole-ICG respectively. Images were
retrieved using a 745 nm excitation filter. These results were encouraging to further study the
efficacy of this probe attachment to hypoxic regions in vivo which will be discussed in the next
chapter.
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Figure 3-4 Fluorescence images of cultured 4T1 breast cancer cells under hypoxic conditions treated with
(a) imidazole ICG, (b) 2-nitroimidazole-ICG, and (c) 4-nitroimidazole-ICG

Figure 3-5 Graphical bars show average radiant efficiency of the hypoxic and normoxic dishes of the
imidazole ICG (5), 2-nitroimidazole-ICG (4), and 4-nitroimidazole-ICG (6).

42

3-4.2 In vivo Imaging

Fluorescent images in Figure 3-6 was taken using the IVIS® Lumina II Imaging System of the
whole mouse body imaging over time (48 h) showing the accumulated uptake of the injected (A)
4-nitroimidazole-ICG, (B) 2-nitroimidazole-ICG and (C) Imidazole-ICG. The imaging system
was set at a 745 nm excitation filter. Fluorescence radiation started to appear at one minute after
injection and the radiant efficiency (Radiant efficiency, unit: p/sec/cm2/sr/(µW/cm2)) plateaued
at 15 min post-injection. As Figure 3-6 (A) shows, injection with 4-nitroimidazole-ICG persisted
for 48 hours and a residual trace was shown at 48 hours post injection which compared to 2nitroimidazole-ICG injection on average performed even better as seen in (B). While imidazoleICG stayed in mice for about three hours and was washed away (C). The data was collected for
the maximum radiation efficiency throughout the 48 h was quantitatively evaluated and
expressed as the mean fluorescence signal (±sd), then compared to same concentration injection
of 2-nitroimidazole-ICG and imidazole-ICG under the same conditions.
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(A)

(B)
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(C)
Figure 3-6 In vivo fluorescence distribution of a mouse injected with 100 µl at 25 µM concentration of
(A) 4-nitroimidazole-ICG (B) 2-nitroimidazole-ICG and (C) Imidazole-ICG. (Image on top left is preinjection and at 1, 5, 15, 30 min, 1 through 10 h, 24 and 48 h post-injection).

Table 3-1 and the graphical representation in Figure 3-7 show the dye washout as a
function of time comparing the three groups of nitroimidazole conjugates; the 4-nitroimidazoleICG shows a higher fluorescent intensity with an uptake at about 1.5-fold over 2-nitroimidazoleICG and about 2.5-fold over the imidazole-ICG at the 15 min peak post-injection. Maximum
radiant efficiency for 4-nitroimidazole-ICG, 2-nitroimidazole-ICG and imidazole-ICG was
measured at 5.05 (±0.57) ×109, 3.39 (±0.33) ×109 and 2.00 (±0.20) ×109 respectively. Strong
fluorescence intensity was still detected 3 hours post-injection at 91 and 69 times higher than the
background for the 4-nitroimidazole-ICG and 2-nitroimidazole-ICG compared to 25 times for
imidazole-ICG.
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Based on these results, the efficacy of 4-nitroimidazole-ICG as a hypoxia targeting
fluorescence probe has been proven to be effective and the dye was retained to a great extent in
hypoxic tumors when compared with imidazole ICG derivative.

Comparisons between multiple groups were made with two-way ANOVA analyses.
When comparing the radiation intensity between the three different conjugates using two-tail ttest, 4-nitrioimidazole-ICG was shown to have a slightly higher intensity than 2-nitrioimidazoleICG. However, this increase was not statistically significant (p > 0.05). On the other hand, 4nitroimidazole-ICG was shown to have a statistically significant increase in intensity when
compared to imidazole-ICG, (p < 0.05).

Table 3-1 Radiant efficiency of the dye conjugates

Time

4 nitroimidazole-pip
9
(x10 )

2 nitroimidazole-pip
9
(x10 )

imidazole ICG
9
(x10 )

Background

0.009 (±0.001)

0.009 (±0.0004)

0.013 (±0.0014)

1 min

3.72 (±0.27)

1.57 (±0.18)

1.14 (±0.003)

15 min

5.05 (±0.57)

3.39 (±0.33)

2.00 (±0.20)

1h

3.80 (±0.79)

2.95 (±0.46)

0.717 (±0.11)

3h

0.84 (±0.28)

0.643 (±0.16)

0.347 (±0.21)

6h

0.39 (±0.16)

0.295 (±0.06)

0.202 (±0.17)

9h

0.29 (±0.09)

0.237 (±0.06)

0.0874 (±0.01)

24 h

0.17 (±0.08)

0.130 (±0.02)

0.0677 (±0.03)

48 h

0.1 (±0.05)

0.0971 (±0.02)

0.0486 (±0.02)
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Figure 3-7 A graphical representation showing the washout as a function of time comparing the three
groups of nitroimidazole conjugates, the 4-nitroimidazole-ICG shows a higher fluorescent intensity after
15 min post-injection.
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3-4.3 Biodistribution Analysis

For dye accumulation and retention analysis in organs, mice were euthanized 48 h post-injection,
and six organs were excised and imaged. Fluorescence intensity of tumor, heart, lungs, kidneys,
spleen and liver were measured. Figure 3-8 shows the average fluorescence intensity distribution
in the organs calculated from all mice groups injected with 4-nitroimidazole-ICG, 2nitroimidazole-ICG and imidazole-ICG, and results show a high retention in tumor and kidneys
in both 4-nitroimidazole-ICG and 2-nitroimidazole-ICG due to slow loss of the dye conjugates
from the tumor as a function of time with excretion via the kidney and liver. The mean value
measured for maximum fluorescence intensity in tumor was 1.39 (±0.44) ×108 for the group
injected with 4-nitroimidazole-ICG and 1.8 (±0.77) ×108 for the group injected with 2nitroimidazole-ICG, these results are still two times higher than the imidazole-ICG which is in
agreement with the in vivo measurements. Figure 3-9 shows the fluorescence images of the
major organs and tumor for the mice group injected with 4-nitroimidazole-ICG at 48 h (2nitrioimidazole-ICG and imidazole-ICG images not shown). Using a two-tail t-test was
performed between 4-nitrioimidazole-ICG and 2-nitrioimidazole-ICG ex vivo data groups and in
agreement with our in-vivo data, there was no significant difference statistically (p > 0.05).
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Figure 3-8 Biodistribution analysis of all mice groups bearing 4T1 tumors after retro-orbital venous sinus
with 100 µl of 4-nitroimidazole-ICG, 2-nitroimidazole-ICG and imidazole-ICG. Bars represent the
retention of the dye 48 h post-injection.

Figure 3-9 Fluorescence images show major organs and tumor for the mice group injected with 4nitroimidazole-ICG at 48 h.
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3-4.4 Immunohistochemistry

To determine the hypoxic status in various tumor groups, we obtained histology images of
stained sections using Zeiss Axio Imager M2 microscope; images were analyzed using ImageJ to
calculate the percentage of the hypoxic area. The percentage of the hypoxic area is defined as the
number of pixels above the threshold in hypoxic areas, over the total number of pixels of the
total area analyzed. We prepared four stained sections of each tumor. The average hypoxic area
percentage from mice treated with 2-nitroimidazole-ICG, 4-nitroimidazole-ICG, and imidazole
ICG was calculated at 1.6% (±0.011), 2.7% (±0.019) and 3% (±0.022) respectively. A
representation of the data analysis is shown in Figure 3-10. These results show no statistical
significant difference of hypoxic area percentage between the 4-nitroimidazole-ICG and 2nitroimidazole-ICG (p > 0.05) and similarly 4-nitroimidazole-ICG and imidazole ICG hypoxic
area percentage also showed no statistical significant difference (p > 0.05).

Figure 3-10 Averaged hypoxic area percentage calculated on all stained tumor slices (sectioned at 10μm)
referenced as 2-nitroimidazole-ICG (4), 4-nitroimidazole-ICG (6), and imidazole ICG (5)
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To validate differences in dye residual accumulation in each tumor, fluorescence images
were obtained from commercial Li-COR imaging system and they are shown in Figure 3-11,
with mice injected with (a) 2-nitroimidazole-ICG, (b) 4-nitroimidazole-ICG, and (c) imidazole
ICG. Using ImageJ software, the average integrated fluorescence density over the tumor sample
area was calculated and mean value of the four different slices in each group was measured at
54.3 (±10.1) and 50.6 (±9.8) for 2-nitroimidazole-ICG and 4-nitroimidazole-ICG, respectively,
compared to 8.5 (±3.1) for imidazole ICG as shown in Figure 3-12. These results indicate
similar fluorescence properties for both 4-nitroimidazole-ICG and 2-nitroimidazole-ICG. The
difference of tumor-integrated density between 4-nitroimidazole-ICG and 2-nitroimidazole-ICG
was not statistically significant (p > 0.05). However, significant difference was observed
between 4-nitroimidazole-ICG and imidazole ICG (p < 0.05). This data confirms our ex vivo
study and confirm dye residual in the tumor area.

Figure 3-11 Li-COR images of 10 μm slices of mice tumors injected with (a) 2-nitroimidazole-ICG (4)
(b) 4-nitroimidazole-ICG (6), and (c) imidazole ICG (5)
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Figure 3-12 A graphical representation showing the average integrated density calculated for all stained
slices imaged with Li-COR imager.
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3-5

Summary

The results presented here demonstrate the feasibility of using the 4-nitroimidazole-ICG as a
hypoxia targeting fluorescence probe. Despite the fact that 2-nitro derivatives have been shown
to be the more useful derivatives for NIR fluorescence imaging of hypoxic tumors, the efficacy
of 4-nitroimidazole-ICG as a hypoxia targeting fluorescence probe has been demonstrated. LiCOR imaging data analysis confirmed very similar fluorescence properties 4-nitroimidazole-ICG
and 2-nitroimidazole-ICG. Analysis of data collected from tumor cells as well as that from the
moue studies showed that both dye-conjugates were retained to a great extent in hypoxic tumors
when compared with imidazole derivative, which is taken to be a realistic standard to probe the
efficacy of each dye. However, the retention of the imidazole derivative in the tumors suggests
that other factors are at work for uptake of the dye conjugates by the tumor. Further studies are
required to illuminate this issue. The histology images of tumor stained sections confirm similar
hypoxic condition of three mice groups.

Currently, 2-nitroimidizole sells for about $343.50/g whereas 4-nitroimidazole for
$1.81/g, so the 2-nitroimdiazole is nearly 190 times as expensive on a per-gram basis [44]. The
cost of 2-nitroimidazole is, therefore, nearly prohibitive for scale-up of the multi-step synthesis
of our dye-conjugates. Based on price considerations alone, the preparation of a 4-nitroimidazole
dye-conjugate was a worthy goal. However, there are concerns about the toxicity of 4nitroimidazole derivatives as reported in earlier work. [45-46] Despite these reports, work by
Wang and coworkers [47] as well as Zhang, Jin, and coworkers [48] showed that the preparation
of 99mTc-labeled 4-nitroimidazole complexes for imaging tumor hypoxia was feasible, and they
reported positive results.
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A cytotoxicity was not performed at this current work, but it is would be required if 4nitroimidazole-piperazine-ICG is to be pursed as a useful imaging agent. However, no
observable difference for the mice injected with either of the three dyes based on post-injection
activity or weight loss, suggesting that there is no significant short-term toxicity was noticed.
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